Hepatitis B virus X protein stabilizes TPM1 to epigenetically inhibit ALDH2 and drive liver cancer progression
4 affiliations
- 1Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogenic Biology and Immunology, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, Jiangsu China
- 2Blood bank, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, Jiangsu China
- 3Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
- 4National Demonstration Center for Experimental Basic Medical Sciences Education, Xuzhou Medical University, Xuzhou, Jiangsu China
Abstract
As a major viral oncogenic factor, the hepatitis B virus (HBV) X protein (HBx) critically contributes to the malignant progression of liver cancer (LC). Although cytoskeletal proteins are implicated in HBx-mediated tumorigenesis, their specific functions and underlying mechanisms in HBx-associated LC remain largely underexplored. Here, we identified that tropomyosin 1 (TPM1), an actin-binding cytoskeletal protein, is significantly overexpressed in HBx-positive LC cells and HBV-associated tumor tissues. Both in vitro and in vivo experiments demonstrated that TPM1 contributes to HBx-induced growth and migration of LC cells. Furthermore, HBx can stabilize TPM1 by disrupting its interaction with SYVN1, an E3 ubiquitin ligase. Additionally, aldehyde dehydrogenase 2 (ALDH2) was identified as a key downstream effector of TPM1. TPM1 markedly downregulates ALDH2 expression, leading to cholesterol accumulation. Specifically, TPM1 binds to histone deacetylase 2 (HDAC2), an epigenetic coregulator, and represses ALDH2 transcription by reducing histone acetylation at the ALDH2 promoter region. Interestingly, HBx enhances the interaction of TPM1with HDAC2, resulting in greater downregulation of ALDH2. Through high-throughput virtual screening and experimental validation, dihydroergotamine mesylate was further identified as a specific TPM1 inhibitor. This compound exerted potent antitumor effects by counteracting HBx-induced cholesterol accumulation and oncogenic phenotypes in LC cells. Collectively, these results delineate a mechanism by which the cytoskeletal protein TPM1 facilitates HBx-induced hepatocarcinogenesis and highlight TPM1 as a promising therapeutic target for HBV-positive LC. suppressing histone acetylation. DHE, a newly identified inhibitor of TPM1, restrains HBx-mediated LC cell biological behaviors.
Graphical Abstract: A schematic illustration of HBx upregulating TPM1 to inhibit ALDH2 and increase cholesterol accumulation, LC cell proliferation, and migration. HBx promotes TPM1 stabilization by inhibiting SYVN1-mediated ubiquitination-dependent degradation of TPM1. HBx enhances TPM1’s interaction with HDAC2 to suppress ALDH2 gene transcription by suppressing histone acetylation. DHE, a newly identified inhibitor of TPM1, restrains HBx-mediated LC cell biological behaviors.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s10565-026-10241-9.
Related
- Shaofu Zhuyu decoction (少腹逐瘀汤) can inhibit the progression of endometriosis fibrosis through the transforming growth factor-β1/ smads signaling pathway mediated by 5’ adenosine monophosphate-activated protein kinase
- CST1 stabilizes GPX4 to suppress ferroptosis and promote bladder cancer progression
- MSRB3 promotes gastric cancer progression and immunotherapy resistance by stabilizing GPX4 to inhibit ferroptosis
- VCP-Regulated LMF2 Stabilizes the Cholesterol Biosynthesis Enzyme HMGCS1 to Drive Cancer Progression and Confer Capecitabine Resistance in Triple-Negative Breast Cancer.
- ESCO1 stabilizes NUFIP2 through acetylation–ubiquitination crosstalk to promote pancreatic cancer progression
BibTeX
@article{kong2026hepatitis,
title = {{Hepatitis B virus X protein stabilizes TPM1 to epigenetically inhibit ALDH2 and drive liver cancer progression}},
author = {Fanyun Kong and Yuxin Wang and Lu Yang and Rong Jiang and Yujie Zhong and Huanyang Zhang and Ensi Bao and Xuanke Liu and Xiangye Liu and Xia Wang and Xiucheng Pan and Suping Qin and Kuiyang Zheng and Chen Li and Renxian Tang and Hongjuan You},
journal = {Cell Biology and Toxicology},
year = {2026},
month = aug,
doi = {10.1007/s10565-026-10241-9},
url = {https://doi.org/10.1007/s10565-026-10241-9},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Hepatitis B virus X protein stabilizes TPM1 to epigenetically inhibit ALDH2 and drive liver cancer progression
AU - Fanyun Kong
AU - Yuxin Wang
AU - Lu Yang
AU - Rong Jiang
AU - Yujie Zhong
AU - Huanyang Zhang
AU - Ensi Bao
AU - Xuanke Liu
AU - Xiangye Liu
AU - Xia Wang
AU - Xiucheng Pan
AU - Suping Qin
AU - Kuiyang Zheng
AU - Chen Li
AU - Renxian Tang
AU - Hongjuan You
PY - 2026
DA - 2026/08/06
JO - Cell Biology and Toxicology
DO - 10.1007/s10565-026-10241-9
UR - https://doi.org/10.1007/s10565-026-10241-9
AB - As a major viral oncogenic factor, the hepatitis B virus (HBV) X protein (HBx) critically contributes to the malignant progression of liver cancer (LC). Although cytoskeletal proteins are implicated in HBx-mediated tumorigenesis, their specific functions and underlying mechanisms in HBx-associated LC remain largely underexplored. Here, we identified that tropomyosin 1 (TPM1), an actin-binding cytoskeletal protein, is significantly overexpressed in HBx-positive LC cells and HBV-associated tumor tissues. Both in vitro and in vivo experiments demonstrated that TPM1 contributes to HBx-induced growth and migration of LC cells. Furthermore, HBx can stabilize TPM1 by disrupting its interaction with SYVN1, an E3 ubiquitin ligase. Additionally, aldehyde dehydrogenase 2 (ALDH2) was identified as a key downstream effector of TPM1. TPM1 markedly downregulates ALDH2 expression, leading to cholesterol accumulation. Specifically, TPM1 binds to histone deacetylase 2 (HDAC2), an epigenetic coregulator, and represses ALDH2 transcription by reducing histone acetylation at the ALDH2 promoter region. Interestingly, HBx enhances the interaction of TPM1with HDAC2, resulting in greater downregulation of ALDH2. Through high-throughput virtual screening and experimental validation, dihydroergotamine mesylate was further identified as a specific TPM1 inhibitor. This compound exerted potent antitumor effects by counteracting HBx-induced cholesterol accumulation and oncogenic phenotypes in LC cells. Collectively, these results delineate a mechanism by which the cytoskeletal protein TPM1 facilitates HBx-induced hepatocarcinogenesis and highlight TPM1 as a promising therapeutic target for HBV-positive LC. suppressing histone acetylation. DHE, a newly identified inhibitor of TPM1, restrains HBx-mediated LC cell biological behaviors. Graphical Abstract: A schematic illustration of HBx upregulating TPM1 to inhibit ALDH2 and increase cholesterol accumulation, LC cell proliferation, and migration. HBx promotes TPM1 stabilization by inhibiting SYVN1-mediated ubiquitination-dependent degradation of TPM1. HBx enhances TPM1’s interaction with HDAC2 to suppress ALDH2 gene transcription by suppressing histone acetylation. DHE, a newly identified inhibitor of TPM1, restrains HBx-mediated LC cell biological behaviors. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s10565-026-10241-9.
SN - 0742-2091
SN - 1573-6822
ER -